NSE: POLYMED | BSE: 531768

Expensive Performer

Download real time

1587.10 -18.10 (-1.13%)

34.27% Gain from 52W Low

91,662 NSE+BSE Volume

NSE 09 Oct, 2026 3:31 PM (IST)

16,087.1

Market Cap

Market Leader

Beta 1Year

Low volatility

Poly Medicure Ltd. share price target and research reports

Name: Latest research reports of Poly Medicure Ltd. authored by Joindre Capital Services and published by - Trendlyne research reports.
Item: Poly Medicure Ltd.
Rating: 5
Author: Joindre Capital Services

Latest analyst research reports with target prices and PDF download for POLYMED, BSE:531768 Poly Medicure Ltd.

Search Inside the pdf :

Poly Medicure Ltd.

12 Aug 2026

1587.10

-1.13%

Poly Medicure Results Update Q1FY27

Results Update: Poly Medicure Ltd.

Joindre Capital Services

Gross margin expanded 495 bps to 73.4%, aided by product mix and the higher gross-margin profile of acquired businesses. However, management expects standalone gross margin to normalize towards...

Poly Medicure Ltd. is trading above its 200 day SMA of 1566.9

Poly Medicure Ltd.

02 Jun 2026

1587.10

-1.13%

Poly Medicure Ltd Result Update Q4FY26

Results Update: Poly Medicure Ltd.

Joindre Capital Services

Cash Position & Capex: Consolidated cash & cash equivalents stood strong at 842 crores despite capex spend of ~296 crores during FY26, providing healthy balance sheet flexibility for future growth initiatives....

Poly Medicure Ltd. is trading above its 200 day SMA of 1566.9

Poly Medicure Ltd.

17 Mar 2026

1587.10

-1.13%

Poly Medicure Ltd.

Buy: Poly Medicure Ltd.

Joindre Capital Services

It is a medical devices company with a product portfolio comprised of 225+ medical devices across 13 specialties including therapy, oncology, anesthesia and respiratory care, urology, gastroenterology, blood management and blood collection, surgery and wound drainage, dialysis, central venous access catheters, veterinary medical devices, and others, supported by a robust distribution network of 950+ distributors across India and globally,...

Poly Medicure Ltd. is trading below its 30 day SMA of 1697.7

Poly Medicure Ltd.

27 Dec 2024

1587.10

-1.13%

POLY MEDICURE LIMITED

Buy: Poly Medicure Ltd.

FundsIndia

Poly Medicure Ltd. is trading above its 200 day SMA of 1566.9

Poly Medicure Ltd.

25 Jul 2024

1587.10

-1.13%

Fresh capacity and exports to drive momentum

Hold: Poly Medicure Ltd.

Target

ICICI Securities Limited

Poly Medicure’s (PolyMed) Q1FY25 performance was boosted by exports (~23% YoY) while domestic business growth (~12% YoY) took a pause on high base. The company has commissioned four new plants that may double its device manufacturing capacity to 1.8bn units p.a by FY25 end.

Poly Medicure Ltd. is trading below its 30 day SMA of 1697.7

Poly Medicure Ltd.

09 Aug 2023, 12:00AM

1587.10

-1.13%

Strong all-round performance

Hold: Poly Medicure Ltd.

Target

ICICI Securities Limited

Poly Medicure reported its all-time high revenues and EBITDA in Q1FY24 driven by solid performance across India (30% YoY growth) and Europe (35%). Softening of raw material prices fuelled a 220bps jump in gross margin. Ahead EBITDA margin is likely to be between 25-27%. Company will commercialise 4 manufacturing facilities in FY24 and launch 10-12 products in critical care segment, which will also likely drive growth and aid margin expansion.

Poly Medicure Ltd. is trading above its 200 day SMA of 1566.9

Poly Medicure Ltd.

30 Jan 2023

1587.10

-1.13%

Growth sustains; margin expands

Accumulate: Poly Medicure Ltd.

Target

ICICI Securities Limited

Poly Medicure’s (Polymed) Q3FY23 performance beats our estimates on all fronts. Revenue grew 23.7% YoY to Rs2.8bn (I-Sec: Rs2.7bn) led by strong demand across segments. EBITDA margin improved 270bps YoY and 140bps QoQ to 24.9%, supported by strong gross margin expansion.

Poly Medicure Ltd. is trading below its 30 day SMA of 1697.7

Poly Medicure Ltd.

08 Nov 2022

1587.10

-1.13%

Strong print

Hold: Poly Medicure Ltd.

Recommendation Target

ICICI Securities Limited

Poly Medicure’s (Polymed) Q2FY23 performance beats our estimates on all fronts.
Revenue grew 23.0% YoY to Rs2.7bn (I-Sec: Rs2.6bn) led by strong demand across segments.